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Summary Despite the advances in pre-, peri- and post-operative medical care of colorectal carcinoma patients, the prognosis has improved
only marginally over recent decades. Thus, additional prognostic indicators would be of great clinical value to select patients for adjuvant
therapy. In previous studies we found that colorectal carcinomas have a marked increase of the urokinase-type of plasminogen activator
(u-PA), and the inhibitors PAI-1 and PAI-2, whereas the tissue-type plasminogen activator (t-PA) is found to be decreased in comparison with
adjacent normal mucosa. In the present study we evaluated the prognostic value of several plasminogen activation parameters, determined
in both normal and carcinomatous tissue from colorectal resection specimens, for overall survival of 136 Dukes' stage B and C colorectal
cancer patients, in relation to major clinicopathological parameters. Uni- and multivariate analyses indicated that a high PAI-2 antigen level in
carcinoma, a low t-PA activity and antigen level and a high u-PA/t-PA antigen ratio in adjacent normal mucosa are significantly associated with
a poor overall survival. A high ratio of u-PA antigen in the carcinomas and t-PA antigen in normal mucosa, i.e. u-PA(C)/t-PA(N), was found to
be predictive of a poor overall survival as well. All these parameters were found to be prognostically independent of the clinicopathological
parameters. Multivariate analysis of combinations of these prognostically significant plasminogen activation parameters revealed that they
are important independent prognostic indicators and have in fact a better prognostic value than their separate components. Based on these
combined parameters, subgroups of patients with Dukes' stage B and C colorectal cancer could be identified as having either a high or a low
risk regarding overall survival. In conclusion, these findings emphasize the relevance of the intestinal plasminogen activation system for
survival prognosis of patients with colorectal cancer and, in the future, might constitute a patient selection criterion for adjuvant therapy.
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Colorectal cancer is one of the leading causes of neoplastic
morbidity and mortality in the Western world. Despite screening of
high-risk individuals and advances in early diagnosis through the
development of better diagnostic techniques, and better medical
care and treatment, the prognosis of colorectal cancer has hardly
changed over recent decades (Ohman, 1985; Enblad et al, 1988;
Sinnige and Mulder, 1991; Winawer et al, 1991; Greenwald, 1992;
Patt, 1993). To date, depth of tumour invasion, lymph node
involvement and distant metastases, which form the basis of most
classification systems, seem to be the most important intervention
criteria and generally used prognostic factors for the survival of
these patients (Beart et al, 1978; Beart, 1990; Sheenan and
Shepherd, 1991; Beahrs, 1992; Williams and Beart, 1992). Primary
treatment of patients with colorectal cancer is surgery. Although
adjuvant therapy provided disappointing results for decades, recent
studies offer some basis for optimism and changes in additional
therapeutic regimens following surgery can be expected (Fisher et
al, 1988; Wolmark et al, 1988; Moertel et al, 1990; Hesketh and
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Bulger, 1991; Krook et al, 1991; O'Connell et al, 1992). However,
additional prognostic factors are necessary and may be of great
importance for outcome prediction and treatment planning of
subgroups ofpatients with colorectal cancer. In particular, patients
with Dukes' stage B and C colorectal carcinoma still pose a major
dilemma regarding the use of adjuvant therapy, as about 50% of
these patients will be cured by surgery alone (Fisher et al, 1988;
Wiggers et al, 1988; Wolmark et al, 1988; Hind et al, 1992).
Therefore, it would be ofgreat value to be able to identify by addi-
tional indicators patients within these histological subgroups with
high or low risk for developing recurrent disease or who have a
poor or good 5-year survival. Some ofthese individuals might then
be selected for specialized adjuvant treatment.
Components of the plasminogen activation system play a
role in the breakdown of the extracellular matrix and basement
membranes. Consequently, they are important contributors to
multifactorial processes such as proliferation, (tumour) cell migra-
tion, tumour invasion and subsequent metastasis formation (Dan0
et al, 1985; Saksela, 1985; Vassalli et al, 1991; Hart, 1992; Schultz
et al, 1992; Duffy, 1993). Plasminogen activators (PAs) are proteo-
lytic enzymes that catalyse the conversion of plasminogen to
plasmin. Two distinct PA types are known: tissue-type PA (t-PA)
and urokinase-type PA (u-PA). t-PA binds to fibrin and is therefore
the major plasminogen activator involved in intravascular dissolu-
tion of blood clots. u-PA and its pro-form (pro-u-PA) bind to the
surface of (cancer) cells via the urokinase receptor and are of
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particular relevance in malignant processes. The activity of plas-
minogen activators is regulated by the plasminogen activator
inhibitors PAI-I and PAI-2. In vitro experiments with human
carcinoma cell lines have shown that invasion and metastasis are
correlated with enhanced expression of u-PA, and that these
processes could be inhibited by antibodies against u-PA and by
blocking of the u-PA receptor (Ossowski et al, 1991; Quax et al
1991; Crowley, 1993).
Many human tumour types have been found to have increased
levels of u-PA, u-PA receptor, PAI-l and/or PAI-2, and decreased
levels of t-PA compared with their corresponding normal tissue
counterparts (Sier et al, 1991; 1993a, b; Sumiyoshi et al, 1991;
Tanaka et al, 1991; Nakamura et al, 1992; de Vries et al, 1994).
These changes found in the plasminogen activation system were
not only contributing to tumour invasion and metastasis but were
also of particular clinical relevance because of their impact on
prognosis. In particular, u-PA, PAI-1 and PAI-2 orcombinations of
these parameters have been found to be ofprognostic relevance to
overall and disease-free survival in breast (Janicke et al, 1990;
Duffy et al, 1992; Foekens et al, 1992; Gr0ndahl-Hansen et al,
1993; Bouchet et al, 1994), urinary bladder (Hasui et al, 1992),
lung (Pedersen et al, 1994), gastric (Nekarda et al, 1994) and
colorectal cancer (Ganesh et al, 1994a; Mulcahy et al, 1994). In
colorectal cancer we recently found that even several plasminogen
activation parameters in normal colorectal mucosa are of prog-
nostic relevance for the overall survival ofthe patients (Ganesh et
al, 1994a). Moreover, Mulcahy et al (1994) recently showed that
high grades ofepithelial cell u-PA staining in Dukes' B colorectal
cancer is associated with a poorer 5-year survival than lower
staining grades. Because of the prognostic impact of PA parame-
ters and the clinical dilemma regarding adjuvant therapy of
patients with colorectal cancer, we evaluated the possibility of
identifying subgroups of these patients with differences in overall
survival by determining the intestinal plasminogen activator
and/or inhibitor levels. Several prognostically relevant clinical and
histological parameters were determined of 136 patients operated
for colorectal carcinoma lesions classified as Dukes' stage B or C.
The prognostic relevance of the plasminogen activation parame-
ters found in the colorectal carcinomas and their corresponding
normal mucosa was compared with that of the clinicopathological
parameters by performing uni- and multivariate survival analyses.
MATERIALS AND METHODS
Patients and study design
All the patients involved in this study were operated on for a histo-
logically proven adenocarcinoma of the colorectum. The opera-
tions were performed from November 1983 to March 1988 at the
Department of Surgery, University Hospital Leiden. Immediately
after resection, fresh samples of carcinomas and adjacent normal
mucosa, taken approximately 10 cm from the tumour, were frozen
and stored at -70°C until extraction. From this group of patients
several clinical and pathological data were evaluated and regis-
tered. The tumours were classified according to the Dukes' stage,
as modified by Astler and Coller (Dukes, 1932; Astler and Coller,
1954; Beart et al, 1978), and 136 patients (60 women and 76 men,
mean age 68.3 ± 0.9 years) with Dukes' B and C lesions, corre-
sponding to UICC (1993) TNM stages I, II, and III, were included
in the study. The pathological data ofthe carcinomas were revised
by one pathologist (JvK), i.e. differentiation of grade into low,
moderate or poor, and number of inflammatory cells and
eosinophils into many, moderate or few. All patients entered the
study at operation date and finished in the event of death (n = 74,
31 women and 43 men) or after a follow-up of at least 5 years at
the common closing date (n = 62, 29 women and 33 men). After
the primary resection or during follow-up, 18.3% (15/82) of the
Dukes' B and 40.7% (22/54) ofthe Dukes' C patients were treated
with either radiotherapy (6 and 16, respectively,), chemotherapy
(three and one, respectively), or surgical resection of a locally
recurrent adenocarcinoma or distant metastasis (three and one
respectively), or a combination ofthese treatments (three and four
respectively).
Tissue extraction and protein concentration
Extracts were prepared from 50- to 100-mg wet tissue samples as
described previously (de Bruin et al, 1987; Sier et al, 1991). In
brief, the samples were homogenized in 1 ml of0.1% (v/v) Tween
80; 0.1 M Tris-HCl buffer (pH 7.5), per 60 mg wet tissue at 0°C.
The homogenates were centrifuged twice at 8000 g for 2.5 min,
4°C and the supernatant was stored at-70°C until analysis. Protein
concentration ofthe supernatant was determined by the method of
Lowry et al (1951).
u-PA and t-PA antigen determination
The u-PA antigen determination was carried out using a sandwich
ELISA according to Binnema et al (1986), with rabbit anti-u-PA
as catching antibody. The samples were incubated overnight
followed by affinopurified goat anti-u-PA IgG as second antibody.
After washing, donkey anti-goat IgG conjugated with alkaline
phosphatase was added andparanitrophenyl phosphate (1 mg ml-1)
was used as substrate. The amount of u-PA antigen in the
samples was calculated from a nine-point standard curve of u-PA
(0-3.3 ng ml-1).
The t-PA antigen level was measured by an ELISA using goat
anti-t-PA as catching antibody and anti-t-PA horseradish peroxi-
dase conjugate as second antibody, according to Rijken et al
(1984), whereas 3,3';5,5' tetramethylbenzidine was used as
substrate. Quantities of t-PA antigen were calculated from
an eight-point standard curve of t-PA (Biopool, Sweden, 0-
32 ng ml-'). Antigen concentrations were expressed finally as
nanogram antigen per milligram protein (ng mg-' protein-').
Assay for plasminogen activator activity
u-PA and t-PA activities were measured enzymatically by a
spectrophotometric assay (Verheijen et al, 1982). In brief, tissue
extracts were incubated with plasminogen, fragments of
fibrinogen and a chromogenic plasmin substrate, resulting in
detection of total plasminogen activator activity. PA activities
were distinguished by adding specific inhibitory antibodies against
t-PA and u-PA (respectively rabbit anti-human t-PA IgG and goat
anti-human u-PA IgM/IgD) to parallel incubations and the activity
of the activators calculated by the amount of inhibition. The
percentage (%) u-PA activity was calculated as 100 times the u-PA
activity divided by the sum ofthe u-PA and t-PA activity. u-PA and
t-PA standard preparations (National Institute of Biological
Standards and Control, London, UK, batch nos 66/46 and 83/517
respectively) were included to express activities in international
units. The inhibiting antibodies used were monospecific, showed
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colorectal carcinomas
All patients Dukes' B Dukes' C PLvalue
(n = 134) (n =82) (n =52)
Normal mucosa
u-PA antigena 2.4 ± 0.1 2.3 +0.1 2.5 +0.2 NS
u-PA actiVityb 52.8 ± 3.1 53.0 +3.7 52.5 +5.5 NS
%-PA activityc 12.1 ± 0.7 12.6 +0.9 11.4 +1.0 NS
t-PAantigena 4.9 ± 0.3 4.9 +0.4 4.8 +0.6 NS
t-PA actiVityb 1477 ± 74 1398 ± 81 1601 +141 NS
u-PA/t-PA antigen ratio 0.8 ± 0.1 0.8 ± 0.1 0.9 +0.1 NS
Carcinomas n= 136 n= 82 n= 54
u-PA antigena 14.0 ± 0.8 12.5 ± 0.7 16.2 ± 1.8 NS
u-PA actiVityb 97.8 ± 7.1 103.6 ± 9.3 89.0 ± 10.7 NS
% u-PA activityc 44.1 ± 1.8 45.7 ± 2.4 41.7 ± 2.9 NS
t-PA antigena 2.2 ± 0.2 2.1 ± 0.2 2.2 ± 0.3 NS
t-PA actiVityb 494 ± 40 494 ± 50 493 ± 68 NS
u-PA/t-PA antigen ratio 11.4 ± 0.9 10.4 ± 1.0 13.0 ± 1.9 NS
n= 133 n= 79 n= 54
PAI-1 antigena 5.0 ± 0.8 4.3 ± 0.8 6.0 ± 1.6 NS
n=131 n=77 n=54
PAI-2 antigena 3.3 ± 0.4 2.5 ± 0.3 4.5 ± 0.9 0.04
n=133 n=82 n=51
u-PA(C)/u-PA(N) antigen ratio 6.9 ± 0.4 6.6 ± 0.5 7.3 ± 0.8 NS
n= 134 n=82 n=52
u-PA(C)/t-PA(N) antigen ratio 5.0 ± 0.4 4.6 ± 0.5 5.6 ± 0.8 NS
Mean ± s.e. ang mg-' protein; bMlU mg-1 protein; c(l 00 x u-PA activity)/(u-PA activity +t-PA activity). C, carcinoma;
N, normal mucosa.
Table 2 Univariate analysis of clinicopathological parameters in relation to overall survival of patients with
Dukes' stage B and C colorectal carcinomas
Parameters Numberof Mediansurvival Hazard ratio
survivors/total () in months (95%Cl, PLvalue)
Gender
Female 29/60 (48.3) 62.9
Male 33/76 (43.4) 47.0 1.2 (0.8-1.9, NS)
Age (years)
< 66.1 34/54 (63.0) > 83.0
* 66.1 28/82 (34.1) 40.0 2.1 (1.3-3.6, 0.004)
Localization
Right colon 20/49 (40.8) 51.5
Leftcolon 42/87 (48.3) 65.4 0.8 (0.5-1.3, NS)
Differentiation grade
Moderate/well 28/61(45.9) 62.2
Poor 34/75 (45.3) 53.5 1.0 (0.7-1.7, NS)
Diameter
<4cm 18/29(62.1) >,79.0
2 4cm 44/107 (41.1) 45.5 1.9 (1.0-3.5, NS)
Inflammatory cells
Many 19/31(61.3) 83.0
Moderate/few 42/99 (42.4) 46.8 1.9 (1.0-3.6, 0.04)
Eosinophils
Many 13/20 (65.0) > 83.0
Moderate/few 48/110 (43.6) 51.0 2.0 (0.9-4.4, NS)
Dukes' stage
Dukes' B 45/82 (54.9) >87.0
Dukes' C 17/54 (31.5) 34.2 1.9 (1.2-3.1, 0.004)
Cl, confidence interval.
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Figure 1 Overall survival curves according to Dukes' st
patients with colorectal cancer. Values are the number c
at the end of follow-up. Univariate hazard ratio 1.9 (950/,
1.2-3.1)
no cross-reactivity and blocked maximum standard u-PA and
t-PA completely. Activator activities were expressed finally as
P=0.004 milli-international units u-PA or t-PA per milligram protein
(mIU mg-' protein).
PAI-1 and PAI-2 antigen determination
Total PAI-l antigen, i.e. latent, active and complexed PAI-1, was
determined using the Tintelize PAI-i ELISA (Biopool, Umeta,
Sweden) without prior denaturation of the samples as described
previously (Sier et al, 1991). In brief, mouse monoclonal anti-
B, 45/37 human PAI-1 was used as catching antibody. After incubation with
the tissue homogenates a goatpolyclonal anti-human PAI-1, conju-
gated to peroxidase, was used to form a sandwich ELISA and
orthophenylenediamine was added as substrate. The assay included
the use ofquenching and non-specific antibodies to exclude falsely
3,17/37 elevated results. In order to increase the sensitivity of the assay
sample volumes of up to 40 ,ul were used, instead of the recom-
mended 20gl, resulting in a detection limit of0.3 ng ml-.
The determination of PAI-2 antigen was performed using the
Tintelize PAI-2 ELISA from Biopool (Sier et al, 1991). The first
antibody used was mouse monoclonal anti-human PAI-2 and the
second was goat polyclonal anti-PAI-2 IgG conjugated to peroxi-
dase. Orthophenylenediamine was added as substrate. Unspecific
72 84 96 response was excluded using quenching antibodies. The detection
limit was decreased to 0.5 ng ml by using 50 gl of homogenate
instead of 20 tl and by increasing sample incubation, conjugate
tage B and C of the incubation and substrate incubation times. Antigen concentrations
rf patients alive-dead
confidence interval were expressed finally as nanogram antigen per milligram protein
(ng mg-' protein).
Table 3 Multivariate analysis of plasminogen activator parameters in colorectal carcinoma and corresponding normal mucosa of
patients with Dukes' stage B and C lesions in relation to the overall survival of the patients
Parameters Number of survivors/total (%) Median survival in months Multivariate hazard ratio
(95% Cl, P.value)
Normal mucosa
t-PA antigena
> 7.39 19/30 (63.3) > 81.0
< 7.39 41/104 (39.4) 46.0 2.0 (1.0-4.2, 0.05)
t-PA activityb
> 1600 30/50 (60.0) > 83.0
< 1600 30/84 (35.7) 44.5 2.1 (1.2-3.8, 0.008)
u-PA/t-PA antigen ratio
< 0.22 17/24 (70.8) > 81.0
> 0.22 43/110 (39.1) 45.0 2.8 (1.2-6.6, 0.02)
Carcinoma
u-PA/t-PA antigen ratio
<3.91 24/38 (63.2) > 83.0
> 3.91 38/98 (38.8) 44.5 1.7 (0.9-3.2, NS)
PAI-2 antigena
< 0.98 23/37 (62.2) > 83.0
> 0.98 38/94 (40.4) 44.5 1.9 (1.0-3.4, 0.05)
u-PA(C)/t-PA(N) antigen ratio
< 6.73 53/104 (51.0) > 83.0
> 6.73 7/30 (23.3) 26.0 2.9 (1.6-5.1, < 0.001)
Cl, confidence interval. ang mg-' protein. bmlU mg-1 protein. C, carcinoma; N, normal mucosa. Multivariate analysis was performed by
adjusting the separate PA parameters to all clinicopathological parameters indicated in Table 2.
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Figure 2 Overall survival curves according to high (> 1600 mlU mg-' protein)
and low (< 1600 mlU mg-' protein) t-PA activity in normal mucosa of patients
with Dukes' stage B and C colorectal carcinoma. Values are the number of
patients alive-dead at the end of follow-up. Univariate hazard ratio 1.9 (95%
confidence interval 1.2-3.2)
Statistical analyses
For the statistical analyses, the clinicopathological parameters
were dichotomized as follows: tumour localization in the colon in
right-sided (from caecum to splenic flexure) vs left-sided (from
splenic flexure up to and including the rectum), Dukes' stage in
Dukes' B vs C, differentiation grade in moderate/well vs poor,
diameters of the tumour in < 4 cm vs > 4 cm and the number of
inflammatory cells and eosinophils in many vs moderate/few. The
cut-off points of the age and PA parameters were determined by
stepwise increasing the level until the point of best discrimination
was found in the Cox proportional hazards model (Cox, 1972), i.e.
the optimal dichotomization.
Differences in PA levels between normal tissue and carcinomas
and between Dukes' B and C patients were statistically tested
(two-sided) using the paired and unpaired Student's t-test, with
separate variance estimation if the standard deviations were signi-
ficantly different according to the F-test. With a selection of the
clinicopathological parameters and plasminogen activation para-
meters in both normal mucosa and carcinoma, univariate survival
analysis was performed with the Cox proportional hazards model,
using the EGRET statistical package (SERC Seattle, WA, USA),
resulting in identification of covariates that were significantly
correlated with the overall survival. The multivariate survival
analyses were performed using the Cox proportional hazards
method by separately adding the significant plasminogen activator
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Figure 3 Overall survival curves according to high (>0.98 ng mg-' protein)
and low (< 0.98 ng mg-' protein) PAI-2 antigen level of the carcinomas of the
patients with Dukes' stage B and C colorectal carcinoma. Values are the
number of patients alive-dead at the end of follow-up. Univariate hazard ratio
2.0 (95% confidence interval 1.1-3.6)
variables to the clinicopathological parameters in order to estimate
their independent prognostic value in the overall survival. The
prognostically significant plasminogen activator parameters were
also analysed in combinations by both uni- and multivariate
analysis. Overall survival curves were constructed by the method
of Kaplan and Meier (1958). Statistical values of P < 0.05 were
considered significant.
RESULTS
In this study 136 patients with Dukes' stage B or C colorectal
carcinoma who had an initially curative resection were included,
most of them were male (55.9%), and the overall survival of the
patients at the common closing date was 45.6%.
Several plasminogen activation-related parameters were evalu-
ated in both carcinoma and adjacent normal colorectal mucosa of
the resection specimens. The distribution of the PA levels was
characterized by high levels of u-PA and low levels of t-PA in
carcinomatous tissue compared with normal colorectal mucosa, as
illustrated in Table 1. Comparing the plasminogen activator levels
between Dukes' stages B and C revealed no differences in the plas-
minogen activator parameters except for PAI-2, which was found
to be higher in Dukes'C tumours. Several clinical and histological
parameters, which could possibly have a relation with the overall
survival of the patients, were also evaluated. After optimal
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Figure 4 Overall survival curves according to high (> 6.73) and low (< 6.73)
antigen ratio of u-PA in carcinomas and t-PA in normal mucosa of the
patients with Dukes' stage B and C colorectal carcinoma. Values are the
number of patients alive-dead at the end of follow-up. Univariate hazard ratio
2.2 (95% confidence interval 1.3-3.5)
dichotomization of the parameters univariate analyses were
performed, and higher age of the patients, relatively few inflam-
matory cells in the carcinomas and advanced Dukes' stage C were
found to be prognostic for a poor survival at the study closing date
(Table 2, Figure 1). Within the different histological stages we
found a gradual decrease in the percentage ofsurvival at the study
closing date (Bp 71.4%; B 49.2%; Cl, 41.2% and C2, 27.0%),
which is in agreement with data from the literature. A large size,
i.e. diameter, of the tumour and a low number of eosinophils
tended to be associated with a poor survival. The overall survival
ofthese patients was found to be independent ofthe other parame-
ters such as gender and localization and differentiation grade ofthe
tumour. Patients receiving additional treatment after the primary
resection or during follow-up were found to have a significantly
(P < 0.01) poorer overall survival than patients having only
primary surgical intervention, 27.0% (10/37) vs 52.5% (52/99)
respectively, with a similar pattern within the groups of patients
having either Dukes' stage B or stage C colorectal cancer.
All the plasminogen activator parameters were also optimally
dichotomized and in the univariate analyses we found that several
of these parameters had a prognostic value for overall survival
(Table 3). In normal mucosa a low level oft-PA activity (Figure 2)
and antigen, a high level of u-PA/t-PA antigen ratio, and in carci-
nomas a high level of u-PA/t-PA antigen ratio and PAI-2 antigen
(Figure 3) were significantly associated with a poor overall
7.7 /
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P-value 0.03 0.02 0.009
Figure 5 Graphic presentation of the percentage survival of subgroups of
Dukes' stage B and C colorectal cancer patients according to combinations
of high (H) or low (L) PAI-2 antigen level (cut-off 0.98 ng mg-' protein) in the
carcinoma with a high or low level of t-PA activity (cut-off 1600 mlU mg-'
protein) in the corresponding normal mucosa. Events indicate the number of
patients dead over total at the end of follow-up. Hazard ratios and
corresponding P-values were obtained by Cox's multivariate analysis. Dotted
line indicates overall survival (45.6%) of all patients at the end of follow-up
survival of the patients. Similarly, a high level of the u-PA(C)/t-
PA(N) antigen ratio (Figure 4) was predictive of a poor survival.
With all these univariately significant plasminogen activator para-
meters multivariate analyses were performed by adjusting each
parameter separately to all the clinicopathological parameters
(Table 3). Only the u-PA/t-PA antigen ratio in the carcinomas lost
its significance whereas all other parameters, both in carcinoma
and normal mucosa, were found to be prognostically independent
ofthe clinicopathological parameters forthe overall survival ofthe
patients. Regrading these parameters, only age and Dukes' stage
were found to be consistently associated with survival in the multi-
variate analyses.
Because several plasminogen activator parameters and the
inhibitor PAI-2 were found to have an independent prognostic
value for overall survival we also evaluated whether a better
subdivision of patients with respect to survival could be made by
combining these parameters and performing uni- and multivariate
analyses. This is illustrated in Figure 5, which shows that patients
with a low PAI-2 in the carcinomas and a high t-PA activity in the
normal mucosa have a good overall survival (92.9%) as opposed
to the patients with a high PAI-2 in the carcinomas and a low t-PA
activity in the normal mucosa (survival 35.6%), whereas the other
two combinations show an intermediate survival. Moreover, these
combined parameters had a significant prognostic value indepen-
dent ofthe clinicopathological parameters.
DISCUSSION
The prognosis of a colorectal carcinoma patient is generally
predicted by the well-established Dukes' classification, based on
the depth of tumour invasion and metastasis (Dukes, 1932; Astler
and Coller, 1954; Dukes and Bussey, 1958). It is known, however,
that in the different Dukes' stages, particularly stage B and C, the
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prognosis of patients can vary considerably. The reason for this
variation could be the fact that the Dukes' stage reflects a stage in
the course of cancer growth rather than its biological behaviour
(Beart et al, 1978; Beart, 1990; Sheehan and Shepherd, 1991;
Beahrs, 1992; Williams and Beart, 1992; Patt, 1993). Although in
recent years several major studies have been performed to evaluate
adjuvant chemotherapy for colorectal cancer (Fisher et al, 1988;
Wolmark et al, 1988; Moertel et al, 1990; Hesketh and Bulger,
1991; Krook et al, 1991; O'Connell et al, 1992), it remains ofgreat
relevance to evaluate other (biological) features for their prog-
nostic impact and patient selection. This could be helpful in clin-
ical decisions, and would possibly offer a better approach to
adjuvant therapy planning. The role of plasminogen activators in
neoplastic growth is well established by in vitro and clinical
studies. The plasminogen activators and their inhibitors play a key
role in the proteolytic cascade that is responsible for the break-
down of several components of the extracellular matrix, which
surrounds the tumour cells. This process results in invasion and
subsequently metastasis formation (Dan0 et al, 1985; Saksela,
1985; Vassalli et al, 1991; Ossowski et al, 1991; Quax et al, 1991;
Hart, 1992; Schultz et al, 1992; Crowley et al, 1993; Duffy, 1993).
We determined several components of the PA system in carcino-
matous tissue and adjacent normal mucosa in a subgroup of 136
Dukes' stage B or C colorectal carcinoma patients, and evaluated
their prognostic value for overall survival in comparison with
several major clinicopathological parameters.
From the clinicopathological parameters, higher age of the
patient (> 66.1 years), Dukes' stage C, and moderate to few inflam-
matory cells in the carcinoma were significantly associated with
poor overall survival of the patients, whereas a diameter of the
tumour .4 cm and the presence ofrelatively few eosinophils in the
carcinoma tended to be associated. The observation that a severe
intratumoral inflammatory reaction, mostly lymphocytic and
eosinophilic infiltration, is associated with a better survival in
colorectal cancer has also been reported by others (Watt and
House, 1978; Nacopoulou et al, 1981; Pretlow et al, 1983; Ponz de
Leon et al, 1992). The inflammatory response within these malig-
nancies could be considered as an attempt ofthe host to enclose the
carcinomatous tissue and to destroy cancer cells. However, its
exact role in cancer prognosis in general remains to be established.
In agreement with our previous study we did not find differentia-
tion and localization of carcinomas within the large bowel to have
an impact on survival (Ganesh et al, 1994a). Regarding the PA
parameters we found that a high u-PA/t-PA antigen ratio and a high
PAI-2 antigen level in carcinomas was associated with a poor
overall survival, but only the latter remained significant in the
multivariate analysis. In contrast to Mulcahy et al (1994) and Sato
et al (1995), who recently reported a positive association between
epithelial u-PA staining and the survival of colorectal cancer
patients, we found no relation between survival and u-PA. The only
association we did find recently in this context is a highly signifi-
cant prognostic impact of the u-PA receptor level on colorectal
cancer survival, also within Dukes' B and C (Ganesh et al, 1994b).
The prognostic value of a high PAI-2 antigen level was found to be
independent ofthe severity ofthe inflammatory reaction within the
carcinoma. This finding was remarkable as there is some evidence
that PAI-2 is involved in inflammatory processes (Schwartz and
Bradshaw, 1992). Our study once more reveals that a low t-PA
level (antigen and activity) and a high u-PA/t-PA antigen ratio in
normal mucosa of patients with colorectal cancer, and a high
u-PA(C)/t-PA(N) antigen ratio are significantly associated with
poor overall survival of the patients. Thus, also in a subgroup of
colorectal carcinoma patients, i.e. Dukes' stage B and C, several
PA parameters in both carcinoma and adjacent normal mucosa
seem to be of major prognostic value for overall survival. In recent
years several studies have been reported that surveyed the relation
between plasminogen activators and inhibitors in other human
malignancies and the prognosis of the patients. Most of these
studies have been carried out in breast cancer and show that high
u-PA and PAI-I antigen levels are associated with the survival of
the patients, independent of other prognostic factors, including
lymph node status (Janicke et al, 1990; Duffy et al, 1992; Foekens
et al, 1992; Gr0ndahl-Hansen et al, 1993; Bouchet et al, 1994).
Because of the fact that these PA parameters could discem patients
at high risk of developing recurrent disease or having a poor
survival in the node-negative group, they already form the basis for
selection ofpatients for further treatment with chemotherapy. Also,
high levels of u-PA, PAI-I and PAI-2 have been found in carci-
nomas of the stomach and oesophagus (Nishino et al, 1988; Takai
et al, 1991; Tanaka et al, 1991; Nakamura et al, 1992; Sier et al,
1993b). Moreover, recent reports of Nekarda et al (1994), Heiss et
al (1995), and our group (Ganesh et al, 1996) have shown that these
parameters are of prognostic value for the survival of patients with
gastric cancer, PAI-1 being an independent prognostic factor.
Furthermore, a high u-PA antigen level in urinary bladder cancer
(Hasui et al, 1992) and a high PAI-I antigen level in pulmonary
adenocarcinoma (Pedersen et al, 1994) have also been reported to
be of prognostic value for the survival of patients. In contrast to
these studies we did not find PAI-I to be ofprognostic significance,
as opposed to PAI-2, which was found to be independently associ-
ated with overall survival of Dukes' stage B or C colorectal cancer
patients. It is known that in colorectal cancer the presence ofmetas-
tasis has more influence on prognosis than the rate of invasion.
Therefore, it could be postulated that the PAI-2 antigen level of the
carcinomas might indicate the metastatic potential of colorectal
cancer because of its independent prognostic impact on survival of
these patients. However, in breast cancer opposite findings have
been reported, i.e. a high PAI-2 level was associated with a rela-
tively good prognosis, particularly in patients with a high tumour u-
PA or PAI-I level. It was speculated that in breast tumours PAI-2
acts as a true inhibitor of u-PA activity (Bouchet et al, 1994;
Foekens et al, 1995). The origin of the differences in the associa-
tion ofPAI-I and PAI-2 with survival prognosis between breast and
colorectal cancer is unclear and remains to be elucidated.
In almost all prognostic studies, the plasminogen activator para-
meters have been determined in carcinomatous tissue. In gastric and
colorectal carcinoma patients, however, the t-PA level in normal
mucosa seems also to be associated with survival (Ganesh et al,
1994a, 1996 and this study). This cannot be attributed to a cancer
patient's specific mucosal plasminogen activator phenotype as the
t-PA level in patients' colorectal mucosa was previously found to be
identical to that of unaffected mucosa of inflammatory bowel
disease patients (de Bruin et al, 1988). The fact thatpathophysiolog-
ical parameters of normal mucosa can be of prognostic value is
supportedby other studies. Increased cellularproliferation in normal
mucosa of patients with colorectal cancer, for instance, has been
found to be an independent prognostic variable for survival
(Sandforth et al, 1991; Al-Sheneber et al, 1993). In this study,
several PA parameters in both normal colorectal mucosa
and carcinoma were found to be ofprognostic relevance. However,
to determine whether the separate PA parameters give maximal
information regarding the prognostic value ofthe PA system in our
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patients, the same analyses were performed with combinations of
the single parameters. All combinations ofthe separate PA parame-
ters had a significant prognostic impact with respect to overall
survival and were independent from the clinicopathological parame-
ters. Furthermore, and more importantly, the prognostic value of
most of the combinations was found to be better than that of the
separate PA parameters. For instance, the combination of PAI-2(C)
antigen >0.98 with t-PA(N) activity <1600 had the best prognostic
value with a multivariate hazard ratio of 14.4 (P = 0.009). As
demonstrated in Figure 5 this combination not only results in the
identification ofhigh-risk patients (survival 35.6%), but also identi-
fies those patients who have a good prognosis (survival 92.9%)
within the group of Dukes' stage B and C colorectal carcinoma.
That combinations ofPA parameters provide betterprognostic indi-
cators is supported by studies ofJanicke et al (1991), Bouchet et al
(1994), andFoekens et al (1995) showing that combinations ofu-PA
with PAI-1 and/or PAI-2 in breast cancer result in abetter identifica-
tion of high-risk patients for recurrent disease, even within
subgroups ofpatients divided according to lymph node involvement
or menopausal status. However, a final model, also in our study,
cannot be given yet because new prognosis-related PA parameters
are still emerging and most studies did not include enough patients
to do so. Nevertheless our findings might, in the future, have direct
clinical implications because patients with Dukes' stage B or C
colorectal carcinoma could be further selected on basis of PA para-
meters and treated with specialized post-operative adjuvant therapy.
In conclusion, determination of plasminogen activators and
their inhibitors in intestinal tissue could be of particular clinical
relevance with respect to survival of patients with colorectal
cancer. In Dukes' stage B and C colorectal carcinoma, a low t-PA
activity and antigen level, ahigh u-PA/t-PA antigen ratio in normal
mucosa, a high PAI-2 antigen level in carcinoma and a high
u-PA(C)/t-PA(N) antigen ratio are associated with poor overall
survival of the patients, independent of the clinicopathological
parameters. Combining these parameters results in even better
prognostic parameters for overall survival of these patients.
Moreover, these combinations identify subgroups of patients with
good or poor overall survival in patients with Dukes' stage B and
C colorectal carcinoma. These combined PA parameters may
provide clinically useful prognostic markers, through which
patients with Dukes' stage B or C colorectal carcinoma can be
selected further for adjuvant therapy.
ABBREVIATIONS
ELISA, enzyme-linked immunosorbent assay; PAI, plasminogen
activator inhibitor; t-PA, tissue-type plasminogen activator; u-PA,
urokinase-type plasminogen activator.
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